Compare Tenet Healthcare Corporation (THC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tenet Healthcare Corporation vs TransMedics Group Inc — how do they compare? Tenet Healthcare Corporation trades at $267.21 (market cap $20.89B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Tenet Healthcare Corporation is far larger — about 6.7× TransMedics Group Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| THC | TMDX | |
|---|---|---|
Market Cap | $20.89B | $3.10B |
Sector | Health | Technology |
52-Week High | $262.63 | $150.42 |
52-Week Low | $161.37 | $61.99 |
Enterprise Value | $31.97B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tenet Healthcare (THC) trades at $266.15, up 2.39% today, with strong technical momentum including a golden cross formation. The stock shows robust fundamentals with a P/E of 10.03, net income margin of 9.9%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with EPS of $6.12 versus $4.26 estimate, driving positive analyst sentiment.
Outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target, though investors should monitor policy headwinds in healthcare and the stock's proximity to 52-week highs. The company's ambulatory growth and raised 2026 guidance support continued upside potential despite net cash flow challenges.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
